Evidence map›Paper›PMID 39006806›Full record

ReviewThe Journal of clinical and aesthetic dermatology2024

Platelet-Rich Plasma for the Treatment of Atopic Dermatitis: A Literature Review.

Shifa Nurzahra Zaki, Mardyansyah, Caroline Oktarina, Reza Yuridian Purwoko, Hans Utama Sutanto

Abstract readReview
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shifa Nurzahra ZakiDr. Zaki is with the Faculty of Medicine at Trisakti University in Jakarta, Indonesia.
MardyansyahDr. Mardyansyah is with the Faculty of Medicine, Trisakti University, Jakarta, Indonesia.
Caroline OktarinaDr. Oktarina is with the Regenerative Medicine and Research Institute at Mandaya Hospital Group in Jakarta, Indonesia.
Reza Yuridian PurwokoDr. Purwoko is with the Regenerative Medicine and Research Institute at Mandaya Hospital Group in Jakarta, Indonesia.
Hans Utama SutantoDr. Sutanto is with the Regenerative Medicine and Research Institute at Mandaya Hospital Group in Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Atopic dermatitis (AD) is a chronic inflammatory skin disease which is associated with a significantly decreased quality of life. Overall, the conventional treatment approaches for moderate to severe AD are prone to relapses. Hence, the exploration of new adjuvant therapies, such as the use of platelet-rich plasma (PRP), is expected to enhance the effectiveness of existing interventions, which remain paramount in improving the quality of life for patients with moderate to severe relapsing AD. Methods: The literature search primarily focused on original English-language articles on PRP as a therapeutic approach for the management of adult AD. Literature reviews, systematic literature, and meta-analyses were excluded. The databases searched include PubMed/Medline, Science Direct, and Cochrane, up to October 2023. Seven articles were reviewed. Results: PRP is reported to be used as a therapy for AD in both injectable and topical forms. Various studies showed that PRP could significantly reduce free radical accumulation, proinflammatory mediators, provide healing environment, and restore the metabolic activity disruption. Clinically, PRP therapy was reported to improve clinical symptoms, patient's satisfaction, quality of life, and reduce frequent recurrence. Mild side effects (pain and ecchymosis) due to the injection were reported. Another advantage is that it is safe to be used in pregnant and breastfeeding women. Limitations: Heterogeneity of methods in preparing PRP and further research with larger scale standardized protocols are warranted. Conclusion: PRP yields favorable outcomes when used in AD treatment and can serve as an alternative for moderate to severe or refractory AD through its anti-inflammatory and proliferative properties.

Indexed as

atopic dermatitisplasma-rich growth factorsPlatelet-rich plasma

Identifiers

PMID39006806
PMCPMC11238712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.